FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2620125093> ?p ?o ?g. }

• W2620125093 endingPage "57385" @default.
• W2620125093 startingPage "57379" @default.
• W2620125093 abstract "// Liping Lin 1, 4, * , Juanjuan Zhao 2, * , Ning Kong 3, 4 , Yan He 1, 4 , Jiazhu Hu 1, 4 , Fuxi Huang 1, 4 , Jianjun Han 1, 4 and Xiaolong Cao 1, 4 1 Department of Oncology, Panyu Central Hospital, Guangzhou, 511400, China 2 School of Nursing, Sun Yat-sen University, Guangzhou, 510000, China 3 Department of Ophthalmology, Panyu Central Hospital, Guangzhou, 511400, China 4 Cancer Institute of Panyu, Guangzhou, 511400, China * These authors contributed equally to this work Correspondence to: Liping Lin, email: linliping2017@tom.com Keywords: ALK-TKIs, interstitial lung disease, QTc prolongation, non-small-cell lung cancer, meta-analysis Received: April 16, 2017      Accepted: May 03, 2017      Published: May 29, 2017 ABSTRACT Background: To conduct a systematic review and meta-analysis to assess the overall incidence and risk of interstitial lung disease (ILD) and QTc prolongation associated with anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitors (-TKIs) in non-small-cell lung cancer (NSCLC) patients. Results: A total of 1,770 patients from 8 clinical trials were included. The incidences of high-grade ILD and QTc prolongation was 2.5% (95% CI 1.7-3.6%), and 2.8% (95% CI 1.8-4.3%), respectively. Meta-analysis demonstrated that the use of ALK-TKIs in NSCLC patients significantly increased the risk of developing high-grade ILD (Peto OR, 3.27, 95%CI: 1.18–9.08, p = 0.023) and QTc prolongation (Peto OR 7.51, 95% CI, 2.16–26.15; p = 0.002) in comparison with chemotherapy alone. Materials and Methods: A systematic literature search was performed to identify related citations up to January 31, 2017. Data were extracted, and summary incidence rates, Peto odds ratios (Peto ORs), and 95% confidence intervals (CIs) were calculated. Conclusions: The use of ALK-TKIs significantly increases the risk of developing high-grade ILD and QTc prolongation in lung cancer patients. Clinicians should pay attention to the risks of severe ILD and QTc prolongation with the administration of these drugs." @default.
• W2620125093 created "2017-06-05" @default.
• W2620125093 creator A5001103132 @default.
• W2620125093 creator A5015475121 @default.
• W2620125093 creator A5017737983 @default.
• W2620125093 creator A5027195409 @default.
• W2620125093 creator A5034965904 @default.
• W2620125093 creator A5060519536 @default.
• W2620125093 creator A5087143195 @default.
• W2620125093 creator A5090804414 @default.
• W2620125093 date "2017-05-29" @default.
• W2620125093 modified "2023-10-16" @default.
• W2620125093 title "Meta-analysis of the incidence and risks of interstitial lung disease and QTc prolongation in non-small-cell lung cancer patients treated with ALK inhibitors" @default.
• W2620125093 cites W1224937636 @default.
• W2620125093 cites W1971969583 @default.
• W2620125093 cites W1974903221 @default.
• W2620125093 cites W1980277787 @default.
• W2620125093 cites W1992447906 @default.
• W2620125093 cites W1994389066 @default.
• W2620125093 cites W2029098899 @default.
• W2620125093 cites W2050249255 @default.
• W2620125093 cites W2057550630 @default.
• W2620125093 cites W2093706343 @default.
• W2620125093 cites W2096096763 @default.
• W2620125093 cites W2099530756 @default.
• W2620125093 cites W2100235578 @default.
• W2620125093 cites W2104830962 @default.
• W2620125093 cites W2106787323 @default.
• W2620125093 cites W2110835998 @default.
• W2620125093 cites W2134338262 @default.
• W2620125093 cites W2134787029 @default.
• W2620125093 cites W2144539352 @default.
• W2620125093 cites W2162724777 @default.
• W2620125093 cites W2170952317 @default.
• W2620125093 cites W2182181585 @default.
• W2620125093 cites W2208535430 @default.
• W2620125093 cites W2239287815 @default.
• W2620125093 cites W2295354328 @default.
• W2620125093 cites W2314587390 @default.
• W2620125093 cites W2337027259 @default.
• W2620125093 cites W2396862357 @default.
• W2620125093 cites W2566863750 @default.
• W2620125093 cites W2581996620 @default.
• W2620125093 cites W2583931149 @default.
• W2620125093 cites W4375907081 @default.
• W2620125093 doi "https://doi.org/10.18632/oncotarget.18283" @default.
• W2620125093 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5593649" @default.
• W2620125093 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28915678" @default.
• W2620125093 hasPublicationYear "2017" @default.
• W2620125093 type Work @default.
• W2620125093 sameAs 2620125093 @default.
• W2620125093 citedByCount "9" @default.
• W2620125093 countsByYear W26201250932018 @default.
• W2620125093 countsByYear W26201250932019 @default.
• W2620125093 countsByYear W26201250932020 @default.
• W2620125093 countsByYear W26201250932023 @default.
• W2620125093 crossrefType "journal-article" @default.
• W2620125093 hasAuthorship W2620125093A5001103132 @default.
• W2620125093 hasAuthorship W2620125093A5015475121 @default.
• W2620125093 hasAuthorship W2620125093A5017737983 @default.
• W2620125093 hasAuthorship W2620125093A5027195409 @default.
• W2620125093 hasAuthorship W2620125093A5034965904 @default.
• W2620125093 hasAuthorship W2620125093A5060519536 @default.
• W2620125093 hasAuthorship W2620125093A5087143195 @default.
• W2620125093 hasAuthorship W2620125093A5090804414 @default.
• W2620125093 hasBestOaLocation W26201250931 @default.
• W2620125093 hasConcept C117643217 @default.
• W2620125093 hasConcept C120665830 @default.
• W2620125093 hasConcept C121332964 @default.
• W2620125093 hasConcept C126322002 @default.
• W2620125093 hasConcept C143998085 @default.
• W2620125093 hasConcept C2776232967 @default.
• W2620125093 hasConcept C2776256026 @default.
• W2620125093 hasConcept C2777543607 @default.
• W2620125093 hasConcept C2777714996 @default.
• W2620125093 hasConcept C61511704 @default.
• W2620125093 hasConcept C71924100 @default.
• W2620125093 hasConceptScore W2620125093C117643217 @default.
• W2620125093 hasConceptScore W2620125093C120665830 @default.
• W2620125093 hasConceptScore W2620125093C121332964 @default.
• W2620125093 hasConceptScore W2620125093C126322002 @default.
• W2620125093 hasConceptScore W2620125093C143998085 @default.
• W2620125093 hasConceptScore W2620125093C2776232967 @default.
• W2620125093 hasConceptScore W2620125093C2776256026 @default.
• W2620125093 hasConceptScore W2620125093C2777543607 @default.
• W2620125093 hasConceptScore W2620125093C2777714996 @default.
• W2620125093 hasConceptScore W2620125093C61511704 @default.
• W2620125093 hasConceptScore W2620125093C71924100 @default.
• W2620125093 hasIssue "34" @default.
• W2620125093 hasLocation W26201250931 @default.
• W2620125093 hasLocation W26201250932 @default.
• W2620125093 hasLocation W26201250933 @default.
• W2620125093 hasLocation W26201250934 @default.
• W2620125093 hasOpenAccess W2620125093 @default.
• W2620125093 hasPrimaryLocation W26201250931 @default.
• W2620125093 hasRelatedWork W1500891939 @default.
• W2620125093 hasRelatedWork W2025354269 @default.
• W2620125093 hasRelatedWork W2234805389 @default.

• next